Biotech
Regenxbio
Regenxbio raises $150M Convertible Note at $2B valuation
$150M
Total Raised
Convertible Note
Latest Round
2008
Founded
350+
Employees
9600 Blackwell Road, Rockville, MD 20850
1 min read
Quick Facts
Valuation
$2B
Latest Round Size
$150M
Latest Round Date
September 2024
Regenxbio: Convertible Note Funding Round
Regenxbio has successfully raised $150M in Convertible Note funding, reaching a valuation of $2B.
Company Overview
Gene therapy delivery platform
Funding Details
The Convertible Note round was led by Third Rock Ventures, with participation from SV Life Sciences, Biomatics Capital Partners.
Company Information
- Headquarters: 9600 Blackwell Road, Rockville, MD 20850
- Founded: 2008
- Employees: 350+
- Category: Biotech
Investment
Regenxbio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Convertible Note
- SV Life Sciences: Verified investor in Convertible Note
- Biomatics Capital Partners: Verified investor in Convertible Note
Key Investors
Third Rock Ventures
Lead Investor
Verified investor in Convertible Note
SV Life Sciences
Investor
Verified investor in Convertible Note
Biomatics Capital Partners
Investor
Verified investor in Convertible Note
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M